Findings aid antiviral drug discovery
Many viral infections, such as the common cold, cause mild illnesses that the body’s immune system eventually defeats. But when viruses cause severe disease, doctors have few options for effective treatment.
Studying mice with a variety of viral infections, scientists at Washington University School of Medicine in St. Louis have demonstrated a way to dial up the body’s innate immune defenses while simultaneously attacking a protein that many viruses rely on to replicate.
The findings, published Oct. 19 in Nature Immunology, reveal previously unknown weapons in the body’s antiviral immune arsenal and provide guidelines for designing drugs that could be effective against a broad range of viruses. The strategy involves enhancing the body’s interferon signaling system, long understood to be a vital part of antiviral defenses.
“We’ve discovered a new component of the interferon system,” said senior author Michael J. Holtzman, MD, the Selma and Herman Seldin Professor of Medicine. “It does something that other components don’t do, and it works on both sides of the fence: It dials up the body’s internal genes that fight viruses, and it attacks viral proteins directly.”
Holtzman and lead author Yong Zhang, PhD, an instructor in pulmonary medicine, suspect that the researchers’ one-two punch against the virus may explain the large difference in survival rates between control mice and mice genetically engineered to have increased signaling in their interferon systems.
When infected with encephalomyocarditis virus, which causes severe damage to vital organs including the brain, heart and pancreas, 97 percent of the genetically engineered mice survived, compared with none of the control mice. Even when the concentration of the injected virus was increased 100-fold, 82 percent of the genetically altered mice survived. And at 100-fold lower concentrations, all genetically engineered mice survived the infection, compared with only 25-28 percent of the control mice.
Holtzman pointed out that past research by other groups has shown that increasing the amount of interferon directly results in some improvements in fighting viruses, but not to the same extent as the current work. In addition, more modest improvements shown by other investigators usually are accompanied by autoimmune problems resulting from the chronically activated immune response. Despite the strong antiviral immune response seen in the new study, Holtzman and his colleagues reported no evidence of autoimmune disease in these mice.
The Latest on: Antiviral immune response
via Google News
The Latest on: Antiviral immune response
- Cancer Immunotherapy Likely Safe, Effective for Those With HIV, Other Infections, Study Suggestson January 12, 2020 at 8:46 am
Although the researchers state that more studies are needed to validate their findings, they found that patients who also had HIV, HBV, or HCV who were being treated with ICI therapy had similar rates ...
- 6 Signs Your Kid’s Immune System Is Compromised & Needs Attentionon January 10, 2020 at 11:20 am
“Kids that are younger than three have a weak immune response, which makes them susceptible to various viral and bacterial attacks.” Thing is, germs can be a necessary evil when it comes to ...
- Technological Advancements Expand Biopharmaceuticals' Production Capabilitieson January 10, 2020 at 5:00 am
NEW YORK, Jan. 10, 2020 /PRNewswire/ -- The biopharmaceutical industry is driven by multiple factors, all while rapidly evolving in the digital era. The need to engineer drugs to treat emerging ...
- Heterologous viral protein interactions within licensed seasonal influenza virus vaccineson January 10, 2020 at 4:08 am
These studies indicate that, if such interactions persist after vaccines reach the draining lymph node, both dendritic cells and HA-specific B cells may take up multiple viral proteins simultaneously.
- Study paves way for new vaccines to protect infants against infectionson January 9, 2020 at 6:19 am
An mRNA vaccine has been developed which has elicited strong immune responses in mice in the presence of ... rather than delivering a one-time shot of a viral protein. “Around the world, every year, ...
- Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller Universityon January 9, 2020 at 4:30 am
particularly originating from the latent viral reservoir. Initial pre-clinical and clinical research has shown that HIV bNAbs can produce an enhanced, prolonged immune response to HIV, representing a ...
- New Vaccines Protect Infants against Infectionson January 9, 2020 at 2:43 am
Instead of delivering lab-grown viral proteins like a traditional vaccine, mRNA vaccines introduce an mRNA sequence that programs cells to produce antigens to mimic the disease. The result is a more ...
- Sensing of HIV-1 by TLR8 activates human T cells and reverses latencyon January 9, 2020 at 2:29 am
During HIV infection, cell-to-cell transmission results in endosomal uptake of the virus by target CD4+ T cells and potential exposure of the viral ssRNA genome to endosomal Toll-like receptors (TLRs) ...
- Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in miceon January 8, 2020 at 11:24 am
Better vaccine strategies need to be developed to overcome matAb inhibition of infant immune responses. Vaccines with viral vector delivery of antigens have successfully elicited de novo antibody ...
- Nanoparticle Flu Vaccine Provides Protection against Six Viral Strainson January 8, 2020 at 5:14 am
The vaccine proved to have long-lasting immune protection, which was unchanged against viral challenges up to four months after ... nanoparticles induce higher levels of humoral and cellular responses ...
via Bing News